CELLINK welcomes new scientific advisor Professor Robert Langer from MIT and co-founder of Moderna

Professor Robert Langer from the Massachusetts Institute of Technology will be joining CELLINK’s Scientific Advisory Board starting in 2021. Professor Langer is a Lemelson-MIT prize winner, the world’s largest prize for invention, for being one of history’s most prolific inventors in medicine and is one of only 11 Institute Professors at MIT, the highest award that can be bestowed on a faculty member. Dr. Langer has received over 220 major awards.  He is one of 3 living individuals to have received both the United States National Medal of Science (2006) and the United States National Medal of Technology and Innovation (2011). He has been elected to the National Academy of Medicine, the National Academy of Engineering, the National Academy of Science and the National Academy of Inventors. Dr. Langer received his bachelor's degree in Chemical Engineering from Cornell University in 1970 and his Sc.D. in Chemical Engineering from MIT in 1974.  He joined MIT as Assistant Professor of Nutritional Biochemistry in 1978. Dr. Langer has written over 1,500 articles and filed over 1,400 patent applications worldwide, of which more than 900 have been granted.  Dr. Langer’s patents have been licensed or sublicensed to over 400 pharmaceutical, chemical, biotechnology and medical device companies.

“We have had the pleasure of working with Prof. Langer and this talented team at MIT for about 2 years, supporting them to push the boundaries of cutting-edge science with our unique technologies for bioprinting and liquid handling,” said Dr. Héctor Martínez, CTO at CELLINK. “His appointment to our Scientific Advisory Board is part of CELLINK’s strategy to continue building unique bioconvergent technologies and expand our product portfolio in the areas of 3D bioprinting, regenerative medicine, 3D cell culture, drug discovery, diagnostics, biosensors, single-cell omics and bioprocessing. We believe that these areas will shape the future of medicine”.  

CELLINK’s advisory board will now have five advisors, including Prof. Ido Amit at the world-renowned Weizmann Institute of Science in Israel, regarded as a world leader and pioneer in development of single-cell genomic technologies and their application to characterize the immune system; Rolf Claesson, who has served as Chairman of Bayer HealthCare and Tecan Group, as CEO of Bayer Diagnostics, and has held executive management positions within Pharmacia, including director of Hill-Rom and Supervisory Board member of Fresenius Medical Care; Dr. Ali Khademhosseini, who served as Professor at Harvard-MIT, Brigham and Women’s Hospital and at Harvard Medical School, was formerly Levi Knight Professor of Bioengineering, Chemical Engineering, and Radiology at UCLA, and has now been appointed Director and CEO of the Terasaki Institute for Biomedical Innovation; Prof. David Williams of Wake Forest School of Medicine, who is regarded as a leading authority on biomaterials, medical devices, and biocompatibility, and has authored and co-authored over 400 technical papers within his field of expertise.

For further information, please contact:

Erik Gatenholm, CEO                                                                Gusten Danielsson, CFO                             
Phone (Sweden): +46 73 267 00 00                                           Phone (Sweden): +46 70 991 86 04      
Phone (US): +1 (650) 515 5566                                                  Phone (US): +1 (857) 332 2138
[email protected]                                                                Email: [email protected]                               

This information was submitted for publication, through the agency of the contact persons set out above, on November 27, 2020 at 08:00 CET.


Founded in 2016, CELLINK is a global life-science company that provides technologies, products and services to create, understand and master biology. With a focus on the application areas of bioprinting, analysis, and liquid handling and bioprocessing, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical and cosmetic industries. CELLINK’s products are trusted by more than 1,800 laboratories, including ones at all the top 20 pharmaceutical companies, are being used in more than 60 countries, and have been cited in more than 200 publications. CELLINK is creating the future of medicine.

Visit cellink.com to learn more. CELLINK is listed on the Nasdaq Stockholm Main Market under CLNK B.

Latest press releases